Asparaginase and Weed

{Fulldrug} and Weed

Authored by Pin Ng PhD

Edited by Hugh Soames

Advertising: We may earn a commission if you buy anything via our advertising or external links

Asparaginase and Weed


Most people who consume marijuana do so for its mood-altering and relaxing abilities. Weed gives people a high and allows them to relax. However, heavy consumption of weed can cause unwanted results. It can increase the anxiety and depression a person experiences, and it can interact with certain other drugs including Asparaginase. It is important to remember that interactions do occur with all types of drugs, to a great or lesser extent and this article details the interactions of mixing Asparaginase and Weed.


Mixing Asparaginase and Weed


Asparaginase is an enzyme that is used as a medication and in food manufacturing. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. In food manufacturing it is used to decrease acrylamide.

Common side effects when used by injection include allergic reactions, pancreatitis, blood clotting problems, high blood sugar, kidney problems, and liver dysfunction. Use in pregnancy may harm the baby. As a food it is generally recognized as safe. Asparaginase works by breaking down the amino acid known as asparagine without which the cancer cells cannot make protein.

The most common nonhematological adverse reactions of asparaginase erwinia chrysanthemi (recombinant) include abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage (bleeding), stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, and hypokalemia. The most common side effects of asparaginase erwinia chrysanthemi (recombinant) when given in combination with chemotherapy for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma are abnormal liver tests, nausea, muscle and bone pain, and fatigue.

Asparaginase was approved for medical use in the United States in 1978. It is on the World Health Organization’s List of Essential Medicines. It is often made from Escherichia coli (E. coli) or Erwinia chrysanthemi.

The development of JZP-458 as a therapeutic agent for ALL has achieved significant milestones throughout the years. In 1963, asparaginase (ASNase) was identified as an effective antileukemic agent, and subsequent efforts were made to isolate it from bacterial sources and scale up production for clinical trials. Clinical testing with bacterial-derived ASNase commenced in 1966, and in 1978, E. coli–derived ASNase received approval from the United States for the treatment of ALL.

As researchers developed deeper into ASNase treatment protocols, it became evident that different preparations of the enzyme exhibited distinct pharmacokinetic properties, necessitating tailored dosing schedules. This realization prompted further clinical trials to characterize outcomes under various ASNase treatment regimens. Subsequently, pegylated E. coli ASNase was approved in 1994 as a second-line treatment and later in 2006 as a first-line treatment for ALL. Another ASNase variant, ASNase Erwinia chrysantemi, obtained authorization for use in the United Kingdom in 1985 and gained approval from the Food and Drug Administration (FDA) in the United States in 2011.

These developments have significantly influenced treatment strategies and protocols, as evidenced by initiatives such as the Children’s Oncology Group (COG) and the Erwinaze Master Treatment Protocol (EMTP). The COG and EMTP have contributed to the refinement and optimization of ASNase therapy for ALL.

Overall, the milestones in the development of ASNase for ALL treatment highlight the progress made in understanding the unique pharmacokinetic properties of different ASNase preparations and tailoring treatment protocols accordingly. The approval of pegylated E. coli ASNase and ASNase Erwinia chrysantemi has expanded the therapeutic options available for ALL patients. Ongoing research and clinical trials continue to advance our knowledge and improve outcomes in the treatment of this challenging disease.

Numerous clinical studies have been conducted to evaluate the efficacy and safety of Erwinase in the treatment of ALL. One of the primary concerns in ALL treatment is the occurrence of adverse events (AEs) associated with asparaginase therapy. These AEs can range from mild to severe and may include hypersensitivity reactions, hepatotoxicity, pancreatitis, coagulation disorders, and thromboembolism. Therefore, understanding the safety profile of Erwinase is crucial in assessing its overall benefit-risk balance.

The main efficacy outcome measure was demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL.  The results of modeling and simulations showed that for a dosage of 25 mg/m2 administered intramuscularly every 48 hours, the proportion of patients maintaining NSAA ≥ 0.1 U/mL at 48 hours after a dose of Rylaze was 93.6% (95% CI= 92.6%-94.6%).

The safety evaluation of JZP-458 in the phase I clinical trial demonstrated a safety profile comparable to that of other asparaginases. Across all administered dose levels (25 mg/m2 for the i.m. route of administration and 37.5 mg/m for the i.v. route), JZP-458 exhibited favorable tolerability without any unexpected adverse events (AEs), serious AEs, or AEs of grade 3 or higher. Among the treatment-emergent AEs reported, nausea was the most frequently observed in two or more healthy volunteers within each dosing cohort.

A further study has examined the incidence and severity of AEs in a cohort of 199 patients with ALL and treated with Erwinase. The study found that the most common AEs were allergic reactions, pancreatitis, hepatotoxicity, and coagulation disorders. However, the majority of these AEs were manageable with appropriate monitoring and intervention strategies.

Furthermore, the incidence of treatment-emergent AEs, particularly nausea, aligns with the expected side effect profile associated with asparaginase therapy. Nausea has been reported as a common adverse event in previous studies investigating asparaginase-based treatments.

On the other hand, a study claimed that in clinical trials, approximately 25% of patients treated with asparaginase encountered hypersensitivity reactions, with 2% experiencing severe reactions. The onset of the first hypersensitivity event was observed at a median time of 27 days after the initial administration of asparaginase (Erwinia chrysanthemi) (recombinant)-rywn, ranging from 1 to 171 days. Among the reported reactions, rash was the most frequently observed, occurring in 17% of patients. Notably, none of the patients experienced a severe rash. The median time from the first dose to the onset of rash was 33.5 days, with a range of 1 to 127 days.

These results provide valuable insights into the safety of JZP-458 and support its potential as a well-tolerated treatment option for the targeted indication. Further investigations, including larger-scale clinical trials, are warranted to confirm these findings and assess the overall efficacy and safety of JZP-458 in a broader patient population.

Efficacy was evaluated in Study JZP458-201 (NCT04145531), an open-label, multi-cohort, multicenter trial in 102 patients with ALL or LBL with hypersensitivity to E. coli-derived asparaginase as a component of a multi-agent chemotherapeutic regimen. The median age was 10 years with a range of 1 to 24 years. Patients received Rylaze intramuscularly at various dosages.

After the initial treatment cycle with JZP-458, the percentage of patients reaching NSAA levels of at least 0.1 IU/mL within 72 hours was found to be 64% (95% CI=47%-82%) in cohort 1a, 91% (95% CI=84%-97%) in cohort 1b, and 90% (95% CI=81%-98%) in cohort 1c. Within 48 hours, over 95% of patients in each cohort achieved NSAA levels of at least 0.1 IU/mL. Specifically, in cohort 1a, 97% of patients (95% CI=91%-100%) achieved this level, while in cohort 1b, the percentage was 99% (95% CI=96%-100%), and in cohort 1c, it was 96% (95% CI=90%-100%). These findings indicate that the majority of patients across all cohorts achieved the desired NSAA levels within 48 to 72 hours of JZP-458 treatment initiation.

A study was carried out to investigate the safety and efficacy related to JZP-458 phase II and III treatment. Out of the total patients (n= 167), 124 individuals (74.3%) experienced adverse events (AEs) related to the treatment, and among them, 86 patients (51.5%) encountered grade 3 or 4 treatment-related AEs. The most prevalent nonhematologic grade 3 or 4 treatment-related AEs included febrile neutropenia (9.0%), elevated levels of alanine aminotransferase (7.8%), and nausea (5.4%). The authors have also claimed that in total, 21 patients (12.6%) discontinued the use of JZP-458 due to treatment-related AEs. The reasons for discontinuation were pancreatitis (6.0%), allergic reactions (5.4%), including anaphylaxis (1.8%), increased alanine aminotransferase (0.6%), and hyperammonemia (0.6%). It is important to note that the AEs leading to patient deaths were sepsis (cohort 1a, n = 1), aspiration pneumonia (cohort 1b, n = 1), and multiorgan failure (cohort 1b, n = 1). However, it was determined that none of these deaths were directly related to the administration of JZP-458.

The findings indicate that the administration of JZP-458 exhibits effectiveness and a safety profile that aligns with other asparaginases. Therefore, the FDA considered the observed and simulated data as sufficient evidence to fulfill the required efficacy target, forming the basis for their decision. Significantly, JZP-458 offers a solution to one of the prominent challenges in patient care for individuals with ALL/LBL, which is the scarcity of reliable drugs. Its dependable manufacturing process, along with its proven efficacy and safety showcased in AALL1931, makes JZP-458 a promising candidate to address this critical issue.

Asparaginases can be used for different industrial and pharmaceutical purposes.

E. coli strains are the main source of medical asparaginase. Branded formulations (with different chemical and pharmacological properties) available in 1998 include Asparaginase Medac, Ciderolase, and Oncaspar. (Crasnitin has been discontinued.) Spectrila is a recombinant E. coli asparaginase.

Asparaginase produced by Dickeya dadantii (formerly called Erwinia chrysanthemi) instead is known as crisantaspase (BAN), and is available in the United Kingdom under the brand name Erwinase.

One of the E. coli asparaginases marketed under the brand name Elspar for the treatment of acute lymphoblastic leukemia (ALL) is also used in some mast cell tumor protocols.

In July 2006, the U.S. Food and Drug Administration (FDA) granted approval to pegaspargase for the first-line treatment of patients with ALL as a component of a multiagent chemotherapy regimen. Pegaspargase was previously approved in February 1994 for the treatment of patients with ALL who were hypersensitive to native forms of L-asparaginase.

In December 2018, the FDA approved calaspargase pegol-mknl, an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients age 1 month to 21 years. This new product provides for a longer interval between doses compared to other available pegaspargase products. Calaspargase pegol-mknl has received FDA orphan drug designation.

In June 2021, the FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL and lymphoblastic lymphoma (LBL) in people aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase. The FDA granted the application for asparaginase erwinia chrysanthemi (recombinant)-rywn fast track and orphan drug designations.

The most common use of asparaginases is as a processing aid in the manufacture of food. Asparaginases are used as a food processing aid to reduce the formation of acrylamide, a suspected carcinogen, in starchy food products such as snacks, biscuits and fried potato.

The main side effect is an allergic or hypersensitivity reaction; anaphylaxis is a possibility. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors (e.g. progressive isolated decrease of fibrinogen) and anticoagulant factor (generally antithrombin III; sometimes protein C & S as well), leading to bleeding or thrombotic events such as stroke. Bone marrow suppression is common but only mild to moderate, rarely reaches clinical significance and therapeutic consequences are rarely required.

Other common side effects include pancreatitis. These side effects mainly attributes to the dual activity of L.Asparaginase as it can also hydrolysis L.Glutamine to Glutamic acid and ammonia.[medical citation needed]

Acrylamide is often formed in the cooking of starchy foods. During heating the amino acid asparagine, naturally present in starchy foods, undergoes a process called the Maillard reaction, which is responsible for giving baked or fried foods their brown color, crust, and toasted flavor. Suspected carcinogens such as acrylamide and some heterocyclic amines are also generated in the Maillard reaction. By adding asparaginase before baking or frying the food, asparagine is converted into another common amino acid, aspartic acid, and ammonium. As a result, asparagine cannot take part in the Maillard reaction, and therefore the formation of acrylamide is significantly reduced. Complete acrylamide removal is probably not possible due to other, minor asparagine-independent formation pathways.

As a food processing aid, asparaginases can effectively reduce the level of acrylamide in a range of starchy foods without changing the taste and appearance of the end product.

Applications of asparaginase in cancer therapy take advantage of the fact that acute lymphoblastic leukemia cells and some other suspected tumor cells are unable to synthesize the non-essential amino acid asparagine, whereas normal cells are able to make their own asparagine; thus leukemic cells require a high amount of asparagine. These leukemic cells depend on circulating asparagine. Asparaginase, however, catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine, which leads to cell death.

Type I L-asparaginase protein may use the morpheein model of allosteric regulation.

The discovery and development of asparaginase as an anti-cancer drug began in 1953, when scientists first observed that lymphomas in rat and mice regressed after treatment with guinea pig serum. Later it was found out that it is not the serum itself which provoke the tumour regression, but rather the enzyme asparaginase.

After researchers comparing different kinds of asparaginases, the one derived from Escherichia coli and Erwinia chrysanthemi turned out to have the best anti-cancer ability. E. coli has thereby become the main source of asparaginase due to the factor that it is also easy to produce in large amount.

The pharmacokinetics of asparaginase erwinia chrysanthemi (recombinant) (Rylaze) were evaluated in 225 recipients in study JZP458-201 (NCT04145531), an open-label multicenter trial in which asparaginase erwinia chrysanthemi (recombinant) was administered at various dosages and routes, and the results were used to develop a model to predict serum asparaginase activity at various timepoints.

The FDA approval of asparaginase erwinia chrysanthemi (recombinant) (Rylaze) was based on evidence from one ongoing clinical trial (NCT04145531) in 102 children and adult participants with a type of cancer called acute lymphoblastic leukemia/lymphoblastic lymphoma. These participants had developed allergy to another type of asparaginase (E.coli based long acting asparaginase). The trial was conducted in 67 sites across the United States and Canada.

Normal asparaginase costs less than its pegylated version, pegaspargase. However, because it doesn’t stay as long in the body, the injections need to be more frequent, with the result that total cost of treatment may be lower for the pegylated version.

Crisantaspase is the British Approved Name (BAN) for asparaginase obtained from Erwinia chrysanthemi. Colaspase is the BAN of asparaginase obtained from Escherichia coli. The United States Adopted Name of crisantaspase is asparaginase Erwinia chrysanthemi. Elspar, Kidrolase, Leunase and Spectrila are brand names for colaspase, while Erwinase and Erwinaze are brand names for crisantaspase. The pegylated version of colaspase is called pegaspargase.[citation needed] Oncaspar is the brand name of pegaspargase.

Synonyms: (1) crisantaspase biobetter JZP-458, (2) RC-P JZP-458, (3) recombinant Asparaginase erwinia chrysanthemi JZP-458, (4) recombinant asparaginase Erwinia chrysanthemi-rywn, and (5) recombinant crisantaspase JZP-458. US brand name: Rylaze and Code name: (1) JZP 458, (2) JZP-458, (3) JZP458, and (4) PF743.

Erwinase has shown promising efficacy and safety profiles in the treatment of ALL. While adverse events may occur, proper monitoring and management strategies can effectively address these challenges. Further research is needed to better understand the long-term efficacy and safety outcomes of Erwinase, particularly in comparison to other asparaginase formulations. Continued investigation and refinement of treatment protocols will contribute to maximizing the benefits of Erwinase therapy for patients with ALL.


Research has found that anxiety is one of the leading symptoms created by marijuana in users, and that there is a correlation between Asparaginase and Weed and an increase in anxiety.


Anyone mixing Asparaginase and weed is likely to experience side effects. This happens with all medications whether weed or Asparaginase is mixed with them. Side effects can be harmful when mixing Asparaginase and weed. Doctors are likely to refuse a patient a Asparaginase prescription if the individual is a weed smoker or user. Of course, this could be due to the lack of studies and research completed on the mixing of Asparaginase and Weed.


Heavy, long-term weed use is harmful for people. It alters the brain’s functions and structure, and all pharmaceuticals and drugs including Asparaginase are designed to have an impact on the brain. There is a misplaced belief that pharmaceuticals and medication work by treating only the parts of the body affected yet this is obviously not the case in terms of Asparaginase. For example, simple painkiller medication does not heal the injury, it simply interrupts the brains functions to receive the pain cause by the injury. To say then that two drugs, Asparaginase and Weed, dol not interact is wrong. There will always be an interaction between Asparaginase and Weed in the brain11.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from


One of the milder side effects of mixing Asparaginase and Weed is Scromiting. This condition, reportedly caused by mixing Asparaginase and Weed, describes a marijuana-induced condition where the user experiences episodes of violent vomiting, which are often so severe and painful that they cause the person to scream. The medical term for Scromiting by mixing Asparaginase and Weed is cannabinoid hyperemesis syndrome, or CHS.  For these reasons, some people choose to quit smoking weed.


It was first included in scientific reports in 2004. Since then, researchers have determined that Scromiting is the result of ongoing, long-term use of marijuana—particularly when the drug contains high levels of THC, marijuana’s main psychoactive ingredient. Some experts believe that the receptors in the gut become overstimulated by THC, thus causing the repeated cycles of vomiting.


In the long run, a person can become even more depressed. There is a belief that marijuana is all-natural and not harmful to a person’s health. This is not true and Asparaginase and weed can cause health issues the more a person consumes it.


How does Weed effect the potency of Asparaginase?


The way in which the body absorbs and process Asparaginase may be affected by weed. Therefore, the potency of the Asparaginase may be less effective. Marijuana inhibits the metabolization of Asparaginase. Not having the right potency of Asparaginase means a person may either have a delay in the relief of their underlying symptoms.


A person seeking Asparaginase medication that uses weed should speak to their doctor. It is important the doctor knows about a patient’s weed use, so they can prescribe the right Asparaginase medication and strength. Or depending on level of interactions they may opt to prescribe a totally different medication. It is important for the doctor to know about their patient’s marijuana use. Weed is being legalized around the US, so doctors should be open to speaking about a patient’s use of it.


Sideffects of Asparaginase and Weed


Many individuals may not realize that there are side effects and consequences to mixing Asparaginase and Weed such as:


  • Dizziness
  • Sluggishness
  • Drowsiness
  • Shortness of breath
  • Itching
  • Hives
  • Palpitations
  • Respiratory Depression
  • Cardiac Arrest
  • Coma
  • Seizures
  • Death


Interestingly, it is impossible to tell what effect mixing this substance with Weed will have on an individual due to their own unique genetic make up and tolerance. It is never advisable to mix Asparaginase and Weed due to the chances of mild, moderate and severe side effects. If you are having an adverse reaction from mixing Asparaginase and Weed it’s imperative that you head to your local emergency room. Even mixing a small amount of Asparaginase and Weed is not recommended.


Taking Asparaginase and Weed together


People who take Asparaginase and Weed together will experience the effects of both substances. Technically, the specific effects and reactions that occur due to frequent use of Asparaginase and weed depend on whether you consume more weed in relation to Asparaginase or more Asparaginase in relation to weed.


The use of significantly more weed and Asparaginase will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.


People who take both weed and Asparaginase may experience effects such as:


  • reduced motor reflexes from Asparaginase and Weed
  • dizziness from Weed and Asparaginase
  • nausea and vomiting due to Asparaginase and Weed


Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Asparaginase leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.

Mixing weed and Asparaginase


The primary effect of weed is influenced by an increase in the concentration of the inhibitory neurotransmitter GABA, which is found in the spinal cord and brain stem, and by a reduction in its effect on neuronal transmitters. When weed is combined with Asparaginase this primary effect is exaggerated, increasing the strain on the body with unpredictable results.


Weed and Asparaginase affects dopamine levels in the brain, causing the body both mental and physical distress. Larger amounts of Asparaginase and weed have a greater adverse effect yet leading medical recommendation is that smaller does of Asparaginase can be just as harmful and there is no way of knowing exactly how Asparaginase and weed is going to affect an individual before they take it.


Taking Asparaginase and weed together


People who take Asparaginase and weed together will experience the effects of both substances. The use of significantly more Asparaginase with weed will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.


People who take both weed and Asparaginase may experience effects such as:


  • reduced motor reflexes from Asparaginase and weed
  • dizziness from weed and Asparaginase
  • nausea and vomiting of the Asparaginase


Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Asparaginase leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.

Weed Vs Asparaginase


Taking Asparaginase in sufficient quantities increases the risk of a heart failure. Additionally, people under the influence of Asparaginase and weed may have difficulty forming new memories. With weed vs Asparaginase in an individual’s system they become confused and do not understand their environment. Due to the synergistic properties of Asparaginase when mixed with weed it can lead to confusion, anxiety, depression and other mental disorders. Chronic use of Asparaginase and weed can lead to permanent changes in the brain22.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from


Asparaginase Vs Weed


Studies investigating the effects of drugs such as Asparaginase and weed have shown that the potential for parasomnia (performing tasks in sleep) is dramatically increased when Asparaginase and weed are combined. Severe and dangerous side effects can occur when medications are mixed in the system, and sleep disorders are a common side effect of taking weed and Asparaginase together.


When a small to medium amount of weed is combined with Asparaginase, sleep disorders such as sleep apnea can occur. According to the latest data from the US Centers for Disease Control and Prevention (CDC) most ER visits and hospitalizations caused by too much weed were associated with other substances such as Asparaginase.


How long after taking Asparaginase can I smoke weed or take edibles?


To avoid any residual toxicity it is advisable to wait until the Asparaginase has totally cleared your system before taking weed, even in small quantities.


Overdose on Asparaginase and weed


In the case of Overdose on Asparaginase or if you are worried after mixing Asparaginase and weed, call a first responder or proceed to the nearest Emergency Room immediately.


If you are worried about someone who has taken too much Asparaginase or mixed weed with Asparaginase then call a first responder or take them to get immediate medical help. The best place for you or someone you care about in the case of a medical emergency is under medical supervision. Be sure to tell the medical team that there is a mix of Asparaginase and weed in their system.


Excessive Weed intake and result in scromiting, chs, and anxiety disorder.  It is advisable to quit vaping weed if you are feeling these symptoms.

Mixing Asparaginase and weed and antidepressants


Weed users feeling depressed and anxious may be prescribed antidepressant medication. There are some antidepressant users who also use Asparaginase and weed. These individuals may not realize that there are side effects and consequences to consuming both Asparaginase, marijuana and a range of antidepressants.


Studies on weed, Asparaginase and antidepressants is almost nil. The reason for so little information on the side effects of the two is mostly down to marijuana being illegal in most places – although a number of states in the United States have legalized the drug.


Self-medicating with Weed and Asparaginase


A lot of people suffer from depression caused by weed and Asparaginase. How many? According to Anxiety and Depression Association of America (ADAA), in any given year, it is estimated that nearly 16 million adults experience depression. Unfortunately, that number is likely to be wrong due to under reporting. Many people do not report suffering from depression because they do not want to be looked at as suffering from a mental illness. The stigmas around mental health continue and people do not want to be labeled as depressed.


Potential side effects from mixing Asparaginase and weed


Quitting weed to take Asparaginase


Medical professionals say an individual prescribed or taking Asparaginase should not stop using weed cold turkey.  Withdrawal symptoms can be significant. Heavy pot users should especially avoid going cold turkey. The side effects of withdrawal from weed include anxiety, irritability, loss of sleep, change of appetite, and depression by quitting weed cold turkey and starting to take Asparaginase.


A person beginning to use Asparaginase should cut back on weed slowly. While reducing the amount of weed use, combine it with mindfulness techniques and/or yoga. Experts stress that non-medication can greatly improve a person’s mood.


Weed and Asparaginase can affect a person in various ways. Different types of marijuana produce different side effects. Side effects of weed and Asparaginase may include:


  • loss of motor skills
  • poor or lack of coordination
  • lowered blood pressure
  • short-term memory loss
  • increased heart rate
  • increased blood pressure
  • anxiety
  • paranoia
  • increased energy
  • increased motivation


Mixing Asparaginase and weed can also produce hallucinations in users. This makes marijuana a hallucinogenic for some users. Weed creates different side effects in different people, making it a very potent drug. Now, mixing Asparaginase or other mental health drugs with weed can cause even more unwanted side effects.


Mixing drugs and weed conclusion


Long-term weed use can make depression and anxiety worse. In addition, using marijuana can prevent Asparaginase from working to their full potential33.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from Weed consumption should be reduced gradually to get the most out of prescription medication. Marijuana is a drug and it is harmful to individual’s long-term health. Weed has many side effects and the consequences are different to each person who uses it, especially when mixed with Asparaginase.


If you take Asparaginase, and also drink Alcohol or MDMA, you can research the effects of Asparaginase and Alcohol , Asparaginase and Cocaine as well as Asparaginase and MDMA here.


To find the effects of other drugs and weed refer to our Weed and Other Drugs Index A to L or our Weed and Other Drugs Index M-Z.

Or you could find what you are looking for in our Alcohol and Interactions with Other Drugs index A to L or Alcohol and Interactions with Other Drugs index M to Z , Cocaine and Interactions with Other Drugs index A to L or Cocaine and Interactions with Other Drugs index M to Z or our MDMA and Interactions with Other Drugs Index A to L or MDMA and Interactions with Other Drugs Index M to Z.


Asparaginase and Weed

Asparaginase and Weed

Counselling for Weed Addiction; Low Cost - Qualified Therapists - Available Now - 20% Off

We may make a commission if you purchase anything via the adverts or links on this page.


Betterhelp is for anyone suffering from mental health issues. Whether you suffer from anxiety, depression, weed addiction, eating disorders, or just need someone to speak to, Betterhelp can pair you with a qualified therapist.


In the wake of the pandemic, an increasing number of people have sought out therapeutic and conseling services to help with weed cessation. Better Help has seen a massive rise in people seeking help over the last two to three years.


If you or someone you care about is smoking or ingesting a level of weed that makes their life become unmanageable, Betterhelp has counselors and therapists on hand to help for less that $90 per week.

Specializations | Burnout, Anxiety, Depression, Stress, Anger Management, Dependencies, Grief, Seasonal Depressive Disorder, Life Crisis, Smoking Cessation, Weed Cessation (among others)


Betterhelp Cost | The standard fee for BetterHelp therapy is only $60 to $90 per week or $240 to $360 per month.


Key Takeaways |

  • Largest online therapy platform
  • Low cost
  • Good for stopping weed
  • Messaging
  • Live video
  • Phone calls
  • Live chat
  • No lock in contracts
  • Cancel anytime
  • Licensed and accredited therapists


Discounts Available | We have negotiated a generous 20% discount for readers of our website. Press Here to get 20% Off


  • 1
    1.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from
  • 2
    2.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from
  • 3
    3.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from